ストックスクリーナーアプリを入手
3.38
0.00%
0.02
前日終値:
$3.36
開ける：
$3.8
24時間の取引高:
15.64M
Relative Volume:
17.26
時価総額：
$104.75M
収益：
$80.97M
当期純損益:
$-78.31M
株価収益率:
-0.3049
EPS:
-11.0849
ネットキャッシュフロー:
$-129.56M
1週間 パフォーマンス:
-6.92%
1か月 パフォーマンス:
-1.17%
6か月 パフォーマンス:
+48.02%
1年 パフォーマンス:
+107.41%
1日の値動き範囲:
$3.32
$4.22
1週間の範囲:
$3.31
$4.22
52週間の値動き範囲:
$1.325
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
名前
Fortress Biotech Inc
セクター
電話
781-652-4500
住所
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
3.375 | 104.29M | 80.97M | -78.31M | -129.56M | -11.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.44 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.40 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
832.58 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.86 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.83 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-15 | 再開されました | ROTH MKM | Buy |
| 2022-08-04 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-02 | 開始されました | The Benchmark Company | Buy |
| 2019-12-18 | 開始されました | B. Riley FBR | Buy |
| 2018-02-28 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | 開始されました | Rodman & Renshaw | Buy |
| 2017-03-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-10-03 | 開始されました | ROTH Capital | Buy |
すべてを表示
Fortress Biotech Inc (FBIO) 最新ニュース
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy - Stocktwits
FBIO: HC Wainwright & Co. Reiterates Buy Rating on Fortress Biotech | FBIO Stock News - GuruFocus
Fortress Biotech: PRV Windfall and De-Risked Zycubo Economics Support Buy Rating and $17 Target - TipRanks
Fortress Biotech (FBIO) Sells Priority Review Voucher for $205 M - GuruFocus
Fortress Biotech, Inc. and Cyprium Therapeutics Enter Asset Purchase Agreement for $205 Million Rare Pediatric Disease Priority Review Voucher - Quiver Quantitative
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics - GlobeNewswire
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - Yahoo Finance
Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - marketscreener.com
Cyprium Voucher Sale Bolsters Fortress Biotech Liquidity - TipRanks
After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan
Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire
Insider Trends: Is Fortress Biotech Inc part of any ETFEarnings Performance Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap - Seeking Alpha
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average – Here’s What Happened - Defense World
Trade Report: Is Fortress Biotech Inc part of any ETFDividend Hike & Low Volatility Stock Recommendations - baoquankhu1.vn
MSN Money - MSN
Fortress Biotech amends credit agreement with Oaktree - MSN
Behavioral Patterns of FBIOP and Institutional Flows - Stock Traders Daily
What is Fortress Biotech Inc.’s book value per shareJuly 2025 Update & Reliable Intraday Trade Plans - mfd.ru
Does Fortress Biotech Inc. stock benefit from AI growthJuly 2025 Retail & Trade Opportunity Analysis Reports - mfd.ru
Will Fortress Biotech Inc. stock recover faster than peers2025 Market Overview & Intraday High Probability Alerts - mfd.ru
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving AverageWhat's Next? - MarketBeat
Wall Street Recap: How do insiders feel about Fortress Biotech IncDividend Hike & Trade Opportunity Analysis - baoquankhu1.vn
Fortress Biotech, Inc. (NASDAQ:FBIO) Might Not Be As Mispriced As It Looks After Plunging 28% - 富途牛牛
Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower - simplywall.st
Fortress Biotech (NASDAQ:FBIO) Shares Jump Above Average Bulls Prepare For Follow Through - Kalkine Media
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
(FBIOP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Fortress Biotech (NASDAQ:FBIOP) Shares Down 4.7% – What’s Next? - Defense World
Fortress Biotech Leads High-Performing Stocks with 93.1% Return - Markets Mojo
Aug Technicals: Can Fortress Biotech Inc deliver alpha2025 Growth vs Value & Weekly Momentum Picks - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
ETF Watch: How liquid is OS Therapies Incorporated stockIPO Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
How (FBIOP) Movements Inform Risk Allocation Models - Stock Traders Daily
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability - Yahoo Finance
Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy - MarketBeat
Analysts Issue Forecasts for FBIO FY2025 Earnings - Defense World
Fortress Bio gains on FDA approval of copper replacement therapy - MSN
Research Analysts Set Expectations for FBIO FY2025 Earnings - MarketBeat
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease - Stocktwits
Risk Hedge: What are the risks of holding Fortress Biotech IncGap Down & Low Risk Entry Point Guides - baoquankhu1.vn
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO, the First and Only Approved Treatment for Menkes Disease in the United States - marketscreener.com
US FDA approves Fortress Bio and Zydus’ treatment for a rare pediatric disease - whtc.com
Investors Purchase Large Volume of Fortress Biotech Call Options (NASDAQ:FBIO) - MarketBeat
Fortress Biotech (FBIO) Surges After FDA Approval for Zycubo - GuruFocus
US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease - Reuters
Fortress Biotech Gains FDA Approval for Menkes Treatment - TipRanks
Fortress Bio wins FDA nod for Menkes disease drug (FBIO:NASDAQ) - Seeking Alpha
Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo - marketscreener.com
FDA Approves Fortress Biotech's ZYCUBO for Pediatric Menkes Dise - GuruFocus
Fortress Biotech Inc (FBIO) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
1.06%
大文字化:
|
ボリューム (24 時間):